Innoviva, Inc.: Q3 FY2025 earnings call

What management said about Q3 FY2025, from the documents filed with the SEC on 5 November 2025: press release. Guidance figures: 1 new, 1 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Total revenue rose 20%: Total revenue was $107.8 million, against $89.5 million a year earlier, with royalties and net product sales both contributing to the increase. Source
• Operating income fell on one charge: Income from operations was $34.6 million, down 20% from $43.2 million, primarily due to a non-recurring research and development expense. Source
• Gross royalty revenue rose 5%: Gross royalty revenue from GSK was $63.4 million, up from $60.5 million a year earlier. Management described the royalties portfolio as growing 5%. Source
• IST U.S. sales up 52%: U.S. net product sales were $29.9 million, a 52% increase on $19.7 million. This is a third consecutive quarter of greater than 50% year-over-year U.S. sales growth. Source
• Zoliflodacin under Priority Review: Zoliflodacin, developed with GARDP for uncomplicated gonorrhea, is under FDA Priority Review with a PDUFA target action date of December 15, 2025. Source
• $125 million buyback authorized: The Board authorized repurchases of up to $125.0 million of common stock. Timing and amount are at management's discretion, with no termination date. Source

“The royalties portfolio reaffirmed its resilience with 5% growth compared to last year, while IST delivered a third consecutive quarter of greater than 50% year-over-year U.S. sales growth.”

Pavel Raifeld, Chief Executive Officer of Innoviva

Guidance

What changed from last quarter

• New: Board authorized a share repurchase program of up to $125.0 million of common stock. Source
• Ended: Holders of 2025 convertible notes converted $192.5 million of principal into 11.1 million shares in August 2025, before maturity. The 2025 notes no longer appear on the September 30 balance sheet. Source
• New: Acquired a long-acting oral drug delivery platform and related assets from Lyndra Therapeutics, with a $10.2 million upfront payment plus potential milestones and royalties. Source
• New: Invested $15.0 million in a term loan to Armata Pharmaceuticals. Source
• New: Invested $17.5 million in Series B Preferred Stock of Beacon Biosignals, Inc., an AI-driven neurotechnology company. Source

Results and growth drivers

• Total revenue rose 20%: Total revenue was $107.8 million, against $89.5 million a year earlier, with royalties and net product sales both contributing to the increase. Source
• Net income rose on investment gains: Net income was $89.9 million, or $1.30 basic per share, against $1.2 million, or $0.02 basic per share, a year earlier. Diluted EPS was $1.08. Source
• Investment gains drove the swing: Net favorable fair value changes in equity and long-term investments were $62.3 million, against $35.2 million of unfavorable changes a year earlier. Source
• Operating income fell on one charge: Income from operations was $34.6 million, down 20% from $43.2 million, primarily due to a non-recurring research and development expense. Source

Royalties and IST sales

• Gross royalty revenue rose 5%: Gross royalty revenue from GSK was $63.4 million, up from $60.5 million a year earlier. Management described the royalties portfolio as growing 5%. Source
• IST U.S. sales up 52%: U.S. net product sales were $29.9 million, a 52% increase on $19.7 million. This is a third consecutive quarter of greater than 50% year-over-year U.S. sales growth. Source
• Ex-U.S. sales reported alongside: Ex-U.S. net product sales were $17.4 million, bringing total net product sales to $47.3 million, against $27.8 million a year earlier. Source

“We are encouraged by early market receptivity for ZEVTERA ® following its U.S. launch over the summer and look forward to zoliflodacin’s December 15 PDUFA date,”

Pavel Raifeld, Chief Executive Officer of Innoviva

Products and launches

• GIAPREZA led U.S. product sales: GIAPREZA contributed $18.2 million, XACDURO $8.5 million, XERAVA $3.2 million and ZEVTERA $0.1 million of U.S. net product sales in the quarter. Source
• ZEVTERA launch focused on access: ZEVTERA launched commercially in the U.S. in July 2025. Initial activity centered on formulary committees and market access programs. Source
• Prix Galien nominations for two products: ZEVTERA and XACDURO were recently nominated for the 2025 Prix Galien USA Award for Best Pharmaceutical Product. Source

Pipeline and regulatory

• Zoliflodacin under Priority Review: Zoliflodacin, developed with GARDP for uncomplicated gonorrhea, is under FDA Priority Review with a PDUFA target action date of December 15, 2025. Source
• No advisory committee planned: After NDA acceptance in June 2025, the FDA said in its Day-74 letter that it did not plan an Advisory Committee meeting on zoliflodacin. Source
• IDWeek subgroup data presented: In October 2025, IST and GARDP presented three sets of subgroup analyses from the pivotal Phase 3 zoliflodacin trial at IDWeek 2025. Source

“The $125 million share repurchase program underscores our confidence in Innoviva’s prospects, supported by the strength of our balance sheet and cashflows, as we strive to create value for our shareholders,”

Pavel Raifeld, Chief Executive Officer of Innoviva

Costs and margins

• R&D expense rose sharply: Research and development expense was $13,670 thousand for the quarter, against $3,551 thousand a year earlier. The charge is described as non-recurring. Source
• Cost of products sold rose: Cost of products sold, including amortization of inventory fair value adjustments, was $25.6 million, against $10.0 million a year earlier. Source
• SG&A expense edged higher: Selling, general and administrative expense was $27.3 million, against $26.2 million a year earlier. Source

Cash and balance sheet

• Cash reached $476.5 million: Cash and cash equivalents totaled $476.5 million at September 30, 2025, up from $305.0 million at December 31, 2024. Receivables were $93.5 million. Source
• Operating cash flow rose for nine months: Net cash provided by operating activities was $142.4 million for the nine months ended September 30, 2025, against $129.5 million a year earlier. Source
• 2028 convertible notes outstanding: Convertible senior notes due 2028 stood at $257.4 million, net, on the September 30 balance sheet. Source

Capital and shareholder returns

• $125 million buyback authorized: The Board authorized repurchases of up to $125.0 million of common stock. Timing and amount are at management's discretion, with no termination date. Source
• Strategic assets valued higher: Strategic assets held through subsidiaries were valued at $483.0 million at September 30, 2025, against $449.3 million at June 30, 2025. Source
• Diluted share count rose: Diluted shares used to compute EPS were 84,964 thousand for the quarter, against 62,951 thousand a year earlier. Source

Strategy and investment

• Holding company with three parts: Management describes Innoviva as a holding company combining a core royalties portfolio, IST, and a portfolio of strategic investments in healthcare assets. Source
• Armata term loan after Phase 2 data: Innoviva invested $15.0 million in an Armata term loan. Armata recently announced positive Phase 2 data in Staphylococcus aureus bacteremia. Source
• Lyndra drug delivery platform acquired: The Lyndra platform was acquired for a $10.2 million upfront payment, plus potential milestone and royalty payments. Source
• Beacon Biosignals preferred stake: Innoviva invested $17.5 million in Series B Preferred Stock of Beacon Biosignals, an AI-driven neurotechnology company. Source

Coming up, as management said on 5 November 2025

• Zoliflodacin FDA action date: The FDA target action date for zoliflodacin is December 15, 2025, under Priority Review for uncomplicated gonorrhea. Source
• Repurchase execution methods: Repurchases under the program may use open market purchases, privately negotiated transactions, block trades, accelerated repurchases, or exchange transactions, at management's discretion. Source

Figures management reported

Risks management discussed

• Financial: Fair value results on equity holdings moved with share prices, including Armata Pharmaceuticals, in this quarter. Source
• Demand: Early ZEVTERA launch activity centered on formulary access, with $0.1 million of U.S. sales in the quarter. Source
• Operational: Income from operations was reduced by a non-recurring research and development expense in the quarter. Source

Earlier plans management reported on

• Met: Management reports that IST commercially launched ZEVTERA in the U.S. in July 2025. Source
• Not stated: Management said it looks forward to the zoliflodacin PDUFA date of December 15, 2025. Source

Other quarters

• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q4 FY2025 earnings call
• Q2 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.